Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Blood (2025) 146 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2025-1843

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Untargeted metabolomics and machine learning reveal novel non-invasive biomarker panels for diagnosis and risk stratification in extranodal NK/T-cell lymphoma

Yajun Li, Kailin Chen, Hui Zhou

Blood (2025) 146 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2025-7082

Published: 2025

Journal Articles

Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinib

Can Yang, Yajun Li, Bo Ning, Xiaotong Ma, Kun Chen, Gusheng Tang, Zhiyuan Wu, Ming Guan

Blood (2025) 146 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2025-3816

Published: 2025

Journal Articles

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Blood (2025) 146 (Supplement 1): 776.

https://doi.org/10.1182/blood-2025-776

Published: 2025

Journal Articles

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He, Zhiming Li, Ningjing Lin, Ou Bai, Caixia Li, Xiaobo Wang, Yajun Li, Xingli Zhao, Huijing Wu, Xiaorui Fu, Zhihua Yao, Jiuyang Zhang, Ying Chen, Wei Meng, Zhuli Wu, Wenzhi Tian, Yuqin Song

Blood (2025) 146 (Supplement 1): 5358.

https://doi.org/10.1182/blood-2025-5358

Published: 2025

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

Zhou Ouyang, Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6197.

https://doi.org/10.1182/blood-2024-201575

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2024-202471

Published: 2024

Journal Articles

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Yizi He, Caiqin Wang, Yajun Li, Ruolan Zeng, Chen Xia, Yixue Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2024-202252

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Yixue Li, Ruolan Zeng, Chen Xia, Yajun Li, Yizi He, Caiqin Wang, Hui Zhou

Blood (2024) 144 (Supplement 1): 6465.

https://doi.org/10.1182/blood-2024-204718

Published: 2024

Journal Articles

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Ruolan Zeng, Zhou Ouyang, Yajun Li, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Yixue Li, Yinhua Liu, Weiqiang Tang, Qianying Ouyang, Liang Liang, Chang Su, Guige Lu, Xueting Zhu, Qianyu Hu, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6460.

https://doi.org/10.1182/blood-2024-202812

Published: 2024

Journal Articles

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

Caiqin Wang, Yizi He, Yajun Li, Ruolan Zeng, Zhiming Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2024-204698

Published: 2024

Journal Articles

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Chen Xia, Yajun Li, Zhongyi Sun, Lijun Huang, Ruolan Zeng, Yizi He, Caiqin Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2024-200882

Published: 2024

Journal Articles

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2024-194674

Published: 2024

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Untargeted metabolomics and machine learning reveal novel non-invasive biomarker panels for diagnosis and risk stratification in extranodal NK/T-cell lymphoma

Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinib

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only